Neurostimulation Treatment of OSA

Thomaz Fleury Curado, Arie Oliven, Luiz U. Sennes, Vsevolod Polotsky, David W Eisele, Alan R Schwartz

Research output: Contribution to journalReview article

Abstract

Over the past 30 years, hypoglossal nerve stimulation has moved through a development pathway to become a viable treatment modality for patients with OSA. Initial pilot studies in animals and humans laid the conceptual foundation for this approach, leading to the development of fully implantable stimulating systems for therapeutic purposes. These devices were then shown to be both safe and efficacious in feasibility studies. One such closed-loop stimulating device was found to be effective in treating a limited spectrum of apneic patients and is currently approved by the US Food and Drug Administration for this purpose. Another open-loop stimulating system is currently being rigorously tested in a pivotal trial. Collectively, clinical trials of hypoglossal nerve stimulating systems have yielded important insights that can help optimize therapeutic responses to hypoglossal nerve stimulation. These insights include specific patient selection criteria and methods for delivering stimulation to specific portions of the hypoglossal nerve and/or genioglossus muscle. New approaches for activating efferent and afferent motor pathways are currently in early-stage laboratory development and hold some long-term promise as a novel therapy.

Original languageEnglish (US)
Pages (from-to)1435-1447
Number of pages13
JournalChest
Volume154
Issue number6
DOIs
StatePublished - Dec 1 2018

Fingerprint

Hypoglossal Nerve
Patient Selection
Afferent Pathways
Efferent Pathways
Equipment and Supplies
Feasibility Studies
United States Food and Drug Administration
Therapeutics
Clinical Trials
Muscles

Keywords

  • hypoglossal nerve stimulation
  • OSA
  • upper airway stimulation

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Neurostimulation Treatment of OSA. / Fleury Curado, Thomaz; Oliven, Arie; Sennes, Luiz U.; Polotsky, Vsevolod; Eisele, David W; Schwartz, Alan R.

In: Chest, Vol. 154, No. 6, 01.12.2018, p. 1435-1447.

Research output: Contribution to journalReview article

Fleury Curado, T, Oliven, A, Sennes, LU, Polotsky, V, Eisele, DW & Schwartz, AR 2018, 'Neurostimulation Treatment of OSA', Chest, vol. 154, no. 6, pp. 1435-1447. https://doi.org/10.1016/j.chest.2018.08.1070
Fleury Curado, Thomaz ; Oliven, Arie ; Sennes, Luiz U. ; Polotsky, Vsevolod ; Eisele, David W ; Schwartz, Alan R. / Neurostimulation Treatment of OSA. In: Chest. 2018 ; Vol. 154, No. 6. pp. 1435-1447.
@article{ff40f6f55d844452bb0fe8bed7331b33,
title = "Neurostimulation Treatment of OSA",
abstract = "Over the past 30 years, hypoglossal nerve stimulation has moved through a development pathway to become a viable treatment modality for patients with OSA. Initial pilot studies in animals and humans laid the conceptual foundation for this approach, leading to the development of fully implantable stimulating systems for therapeutic purposes. These devices were then shown to be both safe and efficacious in feasibility studies. One such closed-loop stimulating device was found to be effective in treating a limited spectrum of apneic patients and is currently approved by the US Food and Drug Administration for this purpose. Another open-loop stimulating system is currently being rigorously tested in a pivotal trial. Collectively, clinical trials of hypoglossal nerve stimulating systems have yielded important insights that can help optimize therapeutic responses to hypoglossal nerve stimulation. These insights include specific patient selection criteria and methods for delivering stimulation to specific portions of the hypoglossal nerve and/or genioglossus muscle. New approaches for activating efferent and afferent motor pathways are currently in early-stage laboratory development and hold some long-term promise as a novel therapy.",
keywords = "hypoglossal nerve stimulation, OSA, upper airway stimulation",
author = "{Fleury Curado}, Thomaz and Arie Oliven and Sennes, {Luiz U.} and Vsevolod Polotsky and Eisele, {David W} and Schwartz, {Alan R}",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.chest.2018.08.1070",
language = "English (US)",
volume = "154",
pages = "1435--1447",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "6",

}

TY - JOUR

T1 - Neurostimulation Treatment of OSA

AU - Fleury Curado, Thomaz

AU - Oliven, Arie

AU - Sennes, Luiz U.

AU - Polotsky, Vsevolod

AU - Eisele, David W

AU - Schwartz, Alan R

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Over the past 30 years, hypoglossal nerve stimulation has moved through a development pathway to become a viable treatment modality for patients with OSA. Initial pilot studies in animals and humans laid the conceptual foundation for this approach, leading to the development of fully implantable stimulating systems for therapeutic purposes. These devices were then shown to be both safe and efficacious in feasibility studies. One such closed-loop stimulating device was found to be effective in treating a limited spectrum of apneic patients and is currently approved by the US Food and Drug Administration for this purpose. Another open-loop stimulating system is currently being rigorously tested in a pivotal trial. Collectively, clinical trials of hypoglossal nerve stimulating systems have yielded important insights that can help optimize therapeutic responses to hypoglossal nerve stimulation. These insights include specific patient selection criteria and methods for delivering stimulation to specific portions of the hypoglossal nerve and/or genioglossus muscle. New approaches for activating efferent and afferent motor pathways are currently in early-stage laboratory development and hold some long-term promise as a novel therapy.

AB - Over the past 30 years, hypoglossal nerve stimulation has moved through a development pathway to become a viable treatment modality for patients with OSA. Initial pilot studies in animals and humans laid the conceptual foundation for this approach, leading to the development of fully implantable stimulating systems for therapeutic purposes. These devices were then shown to be both safe and efficacious in feasibility studies. One such closed-loop stimulating device was found to be effective in treating a limited spectrum of apneic patients and is currently approved by the US Food and Drug Administration for this purpose. Another open-loop stimulating system is currently being rigorously tested in a pivotal trial. Collectively, clinical trials of hypoglossal nerve stimulating systems have yielded important insights that can help optimize therapeutic responses to hypoglossal nerve stimulation. These insights include specific patient selection criteria and methods for delivering stimulation to specific portions of the hypoglossal nerve and/or genioglossus muscle. New approaches for activating efferent and afferent motor pathways are currently in early-stage laboratory development and hold some long-term promise as a novel therapy.

KW - hypoglossal nerve stimulation

KW - OSA

KW - upper airway stimulation

UR - http://www.scopus.com/inward/record.url?scp=85056754016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056754016&partnerID=8YFLogxK

U2 - 10.1016/j.chest.2018.08.1070

DO - 10.1016/j.chest.2018.08.1070

M3 - Review article

C2 - 30222959

AN - SCOPUS:85056754016

VL - 154

SP - 1435

EP - 1447

JO - Chest

JF - Chest

SN - 0012-3692

IS - 6

ER -